NCT03297710View on ClinicalTrials.gov

TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

December 11, 2017

Primary Completion Date

March 16, 2020

Study Completion Date

April 30, 2021

Conditions
Rectal AdenocarcinomaRecurrent Rectal CarcinomaStage IV Rectal Cancer AJCC v7Stage IVA Rectal Cancer AJCC v7Stage IVB Rectal Cancer AJCC v7
Interventions
OTHER

Quality-of-Life Assessment

Ancillary studies

RADIATION

Radiation Therapy

Undergo radiation therapy

DRUG

Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102

Given PO

Trial Locations (2)

55905

Mayo Clinic, Rochester

85259

Mayo Clinic in Arizona, Scottsdale

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT03297710 - TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery | Biotech Hunter | Biotech Hunter